Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-686117 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | ACTIVE_COMPARATOR | - |
| C | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-686117 | DRUG | Injection solution, Subcutaneous, 1 mg, Once daily, Single dose. |
| Byetta | DRUG | Injection solution, Subcutaneous, 5 mcg, Once daily, Single dose. |
| Placebo | DRUG | Injection solution, Subcutaneous, 1 mg, Once daily, Single dose. |
Inclusion Criteria: * Diagnosis of Type 2 diabetes for ≥ 3 months treated with metformin, thiazolidinedione, or sulfonylurea (either monotherapy or combination) or diet alone (drug naïve) * Fasting plasma glucose: 126 - 240 mg/dL * Hemoglobin A1c: 6 - 10% * Estimated CrCl ≥ 60 mL/min * ALT ≤ 1.5 x ...
Top 20 of 31 competitors
BMS-686117 is an investigational small molecule being developed for the treatment of Type 2 Diabetes. It is a metabolic therapeutic that has been studied in a Phase 1 clinical trial to evaluate its safety, pharmacokinetics, and pharmacodynamics in subjects with the condition.
BMS-686117 is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company conducted a Phase 1 clinical trial of the drug in the United States.
BMS-686117 is in Phase 1 of clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and no active trials are currently listed.
BMS-686117 has been studied in one completed Phase 1 trial, identified as NCT00508287. This randomized, double-blind, placebo-controlled study evaluated the safety, pharmacokinetics, and pharmacodynamics of the drug in 36 subjects with Type 2 Diabetes in the United States.
No alternative names for BMS-686117 have been identified. The drug is known by its development code, BMS-686117, and is being studied by Bristol-Myers Squibb for Type 2 Diabetes.